Associations of Free Triiodothyronine With Sarcopenia Among Patients With Type 2 Diabetes: Cross‐Sectional and Sex‐Stratified Analyses
Journal of Diabetes Research · 2026
DOI: 10.1155/jdr/3134701 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Diabetes Research, 2026. Verfasst von Jing Zhao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Affiliated Hospital of Jiangnan University, Jiangnan University, Wuxi, Jiangsu, China, jiangnan.edu.cn. Hauptthemen laut MEDLINE: Sarcopenia, Diabetes Mellitus, Type 2, Triiodothyronine. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Objective
Sarcopenia is prevalent in Type 2 diabetes mellitus (T2DM). Whether thyroid‐related hormones within the euthyroid range can help identify sarcopenia risk remains unclear. This study was aimed at evaluating the association of euthyroid‐range thyroid markers with sarcopenia and their utility in risk stratification among adults with T2DM.
Methods
We analyzed 1823 adults with T2DM (2019–2023). Sarcopenia was defined per Asian Working Group for Sarcopenia 2019 criteria. Muscle mass was assessed via multifrequency bioelectrical impedance analysis, handgrip strength via dynamometer, and gait speed via 6‐m walk test. Multivariate linear and logistic models were adjusted for demographics, diabetes duration, body mass index, nephropathy, glycated hemoglobin, and antidiabetic medications. Discriminatory ability was evaluated using receiver operating characteristic curves, change in the area under the receiver operating characteristic curve ( Δ AUROC), and net reclassification indices (net reclassification improvement [NRI]; bootstrapped).
Results
Higher free triiodothyronine (FT3) levels correlated with greater muscle mass, handgrip strength, and gait speed. Among thyroid markers, FT3 showed the strongest discrimination for sarcopenia (AUROC = 0.633). The optimal cutoff was 3.62 pmol/L (sensitivity, 85.6% and specificity, 35.7%), although overall performance was modest. Low FT3 independently predicted sarcopenia (odds ratio [OR], 2.26; p = 0.002). The association remained significant in females (OR, 3.29) but not in males (OR, 1.83); no sex interaction was detected. Adding FT3 modestly improved the adjusted model ( Δ AUROC, 0.007; NRI significant at 25th percentile risk).
Conclusion
FT3 provides modest but superior discrimination than thyroxine or thyroid‐stimulating hormone and may support early sarcopenia risk detection in T2DM, particularly at low levels, with a possible sex‐specific pattern but no significant interaction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Affiliated Hospital of Jiangnan University, Jiangnan University, Wuxi, Jiangsu, China, jiangnan.edu.cn.
- Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China, njmu.edu.cn.
Förderung
- National Key Research and Development Program of China
Zitieren
APA
Zhao, J., Zhang, M. T., Yu, D., Shao, Z. Y., Chen, D. S., & Zhu, J. (2026). Associations of Free Triiodothyronine With Sarcopenia Among Patients With Type 2 Diabetes: Cross‐Sectional and Sex‐Stratified Analyses. Journal of Diabetes Research. https://doi.org/10.1155/jdr/3134701
Vancouver
Zhao J, Zhang MT, Yu D, Shao ZY, Chen DS, Zhu J. Associations of Free Triiodothyronine With Sarcopenia Among Patients With Type 2 Diabetes: Cross‐Sectional and Sex‐Stratified Analyses. Journal of Diabetes Research. 2026. doi:10.1155/jdr/3134701
BibTeX
@article{Zhao2026,
author = {Zhao, Jing and Zhang, Mei-Tong and Yu, Dan and Shao, Zi-Yue and Chen, Da-Shuang and Zhu, Jian},
title = {Associations of Free Triiodothyronine With Sarcopenia Among Patients With Type 2 Diabetes: Cross‐Sectional and Sex‐Stratified Analyses},
journal = {Journal of Diabetes Research},
year = {2026},
doi = {10.1155/jdr/3134701}
}
EUVIMED